Background: Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC).
We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).
Methods: Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.
Results: Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.
Conclusion: Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
Written by:
Omlin A, J Pezaro C, Zaidi S, Lorente D, Mukherji D, Bianchini D, Ferraldeschi R, Sandhu S, Dearnaley D, Parker C, Van As N, de Bono JS, Attard G. Are you the author?
Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
Reference: Br J Cancer. 2013 Sep 3;109(5):1079-84.
doi: 10.1038/bjc.2013.446
PubMed Abstract
PMID: 23928659
UroToday.com mCRPC Treatment Section
